When: Q3 2026 MLR normalization

Then: Re-enter position

SELL (trim to 50-75% benchmark weight, do not initiate new longs, hedge with December 2026 puts at 370-380 strike)

• Trailing 32.9% twelve month return is in the rearview mirror and does not protect against gap downs on binary catalysts
• 2.41% dividend yield is a coupon on a depreciating asset while stock trades below 50 SMA at 413.70 and 10 EMA at 396
• Zacks triple inclusions are quantitative mean reversion screens, not qualitative bullish endorsements; screen-driven buying creates one-day demand pockets that get faded
• Neutral analyst's reentry trigger (daily close above 414 on above average volume with RSI crossing 50 and MACD positive) is unlikely before October CMS Star Ratings release
• Insider signal: buybacks paused since Q1 2025 despite 52-week high regime is a meaningful management tell about forward earnings concerns
• MACD at negative 7.24 with signal line at negative 4.84 and histogram at negative 2.40 confirms downside momentum intact
• RSI at 38.34 has not reached 30 oversold threshold, meaning downside momentum has further to run
• ATR at $10.08 indicates ~1% daily movement; breakdown below lower Bollinger Band at $382.33 opens path toward $370 then 200 SMA at $345.31
• Q4 2025 EPS essentially zero; Q1 2026 at $6.90; forward EPS of $22.44 implies 44% rebound that appears to be normalization rather than organic growth
• A 10-15% haircut to forward EPS moves realistic forward P/E from 17.4 to 19-20, which is full multiple for a stock with three pending regulatory binaries
• Reentry requires all three confirmations: 414 close on volume, October Star Ratings at 4 stars or better, and Q2 2026 MLR at or below street estimates

→ vs aggressive: Framing trim as a 'high conviction momentum breakout play in reverse' and talking about 'freeing up capital for the next high conviction setup' is the language of an opportunistic trader, not capital preservation; the job is not to position for the next opportunity but to prevent losses during the binary cluster

→ vs aggressive: Implying we should be making aggressive new short bets or rotating into other setups overreaches; we are not in the business of calling tops

→ vs neutral: The 32.9% trailing return does not protect from a 5-10% gap down on IRS probe or Change Healthcare ruling; it is rearview mirror analysis

→ vs neutral: The 2.41% yield on a stock below its 50 SMA and 10 EMA with negative MACD is not income but a coupon on a depreciating asset; rounding trip to 200 SMA at $345 means collecting dividends while losing ~12% of principal

→ vs neutral: The wait-for-confirmation trigger is 'a prayer' given the 50 SMA at 413.70 acting as overhead resistance; it waits for a signal that the catalyst window has already passed

→ vs neutral: RSI at 38.34 not hitting 30 oversold threshold means 'the easy oversold bounce trade has not even printed yet'; interpreting this as bullish is wrong—downside momentum has further to run before mean reversion is statistically attractive

REDUCE (normalized to SELL)

• Current price near $390, down 10% from July swing high but 13% above the intact 200 SMA at $345
• Trim 25-30% of position at current levels ($390), with additional 15-20% trim orders at $400-$410
• Hold 75% core position for structural quality, 16-year dividend increase streak, and defensive profile
• Hedge core position with Dec 2026 $380-$390 puts to cover October catalyst cluster
• Hard stop at 200 SMA ($345), not the 50 SMA overhead, to avoid being stopped out by normal 1% daily volatility (ATR of $10)
• Re-entry requires: price reclaim of 50 SMA on above-average volume AND neutral-to-positive Star Ratings print in October; Q2 MLR is a tiebreaker, not a gate
• Fed on hold with 85% probability of no cuts in 2026; recession probability only 8%
• Q1 free cash flow of $8 billion demonstrates recovery; trailing 33% return supports holding core
• Insider buyback pause likely capital preservation during Change Healthcare litigation discovery phase, not bearish signal
• Forward EPS maintained at $22.44; 10-15% haircut presented by Conservative analyst is the lower bound of reasonable estimates, not a base case

→ vs aggressive: Calling a test of the 200 SMA in an intact long-term uptrend a 'bear thesis validation' is conflating medium-term correction with structural bear market; the 200 SMA at $345 is 13% below current price and intact

→ vs aggressive: Zacks triple inclusion is not 'distribution signature'—quantitative screens are buying because metrics genuinely screen favorably after the pullback; reversing causation to fit bearish narrative

→ vs aggressive: Probability analysis error: three binaries each with 60% probability of neutral/positive resolution means 15% probability ALL go badly, not the worst-case path being priced; stop at $414 is too tight for 5-10% gap risk

→ vs conservative: Insider buyback pause in Q1 2025 predates current weakness and likely reflects litigation discovery phase restrictions or capital preservation, not bearish signal; overinterpreting to fit thesis

→ vs conservative: EPS haircut of 10-15% is not fact but choosing the lower bound of estimates; forward EPS of $22.44 is equally valid given MLR stabilization per Q1 and moderating medical cost trend per Zacks

→ vs conservative: Three-confirmation re-entry requirement is so restrictive it guarantees missing meaningful recovery; could miss entire $380-$450 move if Star Ratings come in at 3.5 instead of 4.0